Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Lowered by Cutter & CO Brokerage Inc.

Cutter & CO Brokerage Inc. decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% in the third quarter, Holdings Channel.com reports. The fund owned 7,665 shares of the biopharmaceutical company’s stock after selling 111 shares during the period. Regeneron Pharmaceuticals comprises about 1.8% of Cutter & CO Brokerage Inc.’s holdings, making the stock its 8th biggest position. Cutter & CO Brokerage Inc.’s holdings in Regeneron Pharmaceuticals were worth $8,058,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Stephens Consulting LLC purchased a new position in Regeneron Pharmaceuticals in the second quarter worth about $26,000. Sachetta LLC boosted its stake in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the period. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals during the first quarter valued at $28,000. Lynx Investment Advisory purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at $33,000. Finally, Family Firm Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $33,000. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on REGN shares. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Leerink Partners reissued a “market perform” rating and set a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Piper Sandler upped their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research report on Friday, August 23rd. Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Finally, Barclays decreased their price objective on shares of Regeneron Pharmaceuticals from $1,220.00 to $1,080.00 and set an “overweight” rating for the company in a report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,101.00.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded down $0.58 during mid-day trading on Tuesday, hitting $928.03. The stock had a trading volume of 12,333 shares, compared to its average volume of 502,703. The company has a 50 day moving average of $1,083.08 and a two-hundred day moving average of $1,041.32. Regeneron Pharmaceuticals, Inc. has a twelve month low of $772.84 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The firm has a market cap of $102.31 billion, a PE ratio of 24.59, a PEG ratio of 3.20 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same period last year, the business posted $8.79 earnings per share. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.6 EPS for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.